{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:16:57Z","timestamp":1773955017671,"version":"3.50.1"},"reference-count":30,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Primary biliary cholangitis (PBC) is a rare autoimmune liver disease with variation in prevalence, phenotype and prognosis across different geographical regions. Little is known about PBC in Israel. Our aim was to characterize the demography, clinical presentation, treatment patterns and prognosis in a cohort of PBC patients followed in a referral center in central Israel. Methods: Clinical, demographic and laboratory data were collected from the medical records of PBC patients followed at Tel Aviv Medical Center in the years 2003\u20132020. Results: We have identified 189 patients with a confirmed diagnosis of PBC; 92.6% were female and the mean age at diagnosis was 54.7 years. Thirty-nine percent were diagnosed with another autoimmune disease and 5.9% were diagnosed with a PBC-AIH (autoimmune hepatitis) variant syndrome. Ninety-six percent were treated with ursodeoxycholic acid (UDCA) at a mean dose of 13.3 mg\/kg. A total of 28.1% were found with inadequate response to UDCA according to the Toronto criteria, and 53% of the UDCA non-responders were treated with bezafibrate. Younger age at diagnosis, higher baseline levels of alkaline phosphatase (ALP) and gamma-glutamyltransferase (GGT), AIH-PBC variant and positive anti-smooth muscle antibodies (ASMA) were associated with an inadequate UDCA response. In a multivariable analysis, higher ALP at diagnosis (OR = 1.92 CI 1.11\u20133.20 per 50-unit change, p = 0.018) and ASMA (OR = 27.6 CI 2.58\u2013295, p = 0.006) independently predicted inadequate UDCA response. Higher alanine transaminase (ALT), ALP and GGT, lower albumin, younger age at diagnosis and pruritus conferred an increased risk for disease progression. Conclusions: Disease characteristics, treatment patterns, response to therapy and prognosis of a PBC patient cohort in a tertiary center in central Israel were revealed. The results highlight the importance of risk stratification in PBC, specifically in younger patients, those presenting with a high level of liver enzymes and in ASMA-positive patients with an assumed diagnosis of the AIH-PBC variant.<\/jats:p>","DOI":"10.3390\/jcm10194551","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T10:22:42Z","timestamp":1632997362000},"page":"4551","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-World Management of Patients with Primary Biliary Cholangitis\u2014A Retrospective Study from a Tertiary Medical Center in Israel"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9425-4228","authenticated-orcid":false,"given":"Eyal","family":"Yehezkel","sequence":"first","affiliation":[{"name":"Center for Autoimmune Liver Diseases, Department of Gastroenterology, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inbal","family":"Israel","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6397-6604","authenticated-orcid":false,"given":"Inbal","family":"Houri","sequence":"additional","affiliation":[{"name":"Center for Autoimmune Liver Diseases, Department of Gastroenterology, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moshe","family":"Leshno","sequence":"additional","affiliation":[{"name":"Center for Autoimmune Liver Diseases, Department of Gastroenterology, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oren","family":"Shibolet","sequence":"additional","affiliation":[{"name":"Center for Autoimmune Liver Diseases, Department of Gastroenterology, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2956-1867","authenticated-orcid":false,"given":"Ehud","family":"Zigmond","sequence":"additional","affiliation":[{"name":"Center for Autoimmune Liver Diseases, Department of Gastroenterology, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis","volume":"353","author":"Kaplan","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"6560","DOI":"10.1038\/s41598-017-06807-7","article-title":"Underestimated Male Prevalence of Primary Biliary Cholangitis in China: Results of a 16-year cohort study involving 769 patients","volume":"7","author":"Fan","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"25906","DOI":"10.1038\/srep25906","article-title":"Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis","volume":"6","author":"Lleo","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3389\/fimmu.2018.00609","article-title":"Autoantibodies in Autoimmune Liver Disease\u2014Clinical and Diagnostic Relevance","volume":"9","author":"Sebode","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and Age Are Determinants of the Clinical Phenotype of Primary Biliary Cirrhosis and Response to Ursodeoxycholic Acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2017). Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J. Hepatol., 67, 145\u2013172.","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"ref_12","first-page":"49","article-title":"Clinical Updates in Primary Biliary Cholangitis: Trends, Epidemiology, Diagnostics, and New Therapeutic Approaches","volume":"8","author":"Galoosian","year":"2020","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"9151525","DOI":"10.1155\/2021\/9151525","article-title":"The Epidemiology of Primary Biliary Cholangitis in European Countries: A Systematic Review and Meta-Analysis","volume":"2021","author":"Gazda","year":"2021","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/j.ejim.2012.09.004","article-title":"Primary biliary cirrhosis in Southern Israel: A 20 year follow up study","volume":"23","author":"Delgado","year":"2012","journal-title":"Eur. J. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cld.2018.03.001","article-title":"Changes in the Epidemiology of Primary Biliary Cholangitis","volume":"22","author":"Lleo","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000440754","article-title":"Geoepidemiology, Genetic and Environmental Risk Factors for PBC","volume":"33","author":"Zhang","year":"2015","journal-title":"Dig. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1080\/00365521.2019.1669702","article-title":"Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy","volume":"54","author":"Rosina","year":"2019","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/00365521.2019.1606931","article-title":"Biochemical response to ursodeoxycholic acid among PBC patients: A nationwide population-based study","volume":"54","author":"Lund","year":"2019","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2014.01.029","article-title":"Optimising risk stratification in primary biliary cirrhosis: AST\/platelet ratio index predicts outcome independent of ursodeoxycholic acid response","volume":"60","author":"Trivedi","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/apt.13927","article-title":"The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: The additional effect of anti-gp210","volume":"45","author":"Yang","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ueg2.12095","article-title":"Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease","volume":"9","author":"Liberal","year":"2021","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Wilde, A.-C., Lieb, C., Leicht, E., Greverath, L., Steinhagen, L., de Chamorro, N.W., Petersen, J., Hofmann, W., Hinrichsen, H., and Heyne, R. (2021). Real-World Clinical Management of Patients with Primary Biliary Cholangitis\u2014A Retrospective Multicenter Study from Germany. J. Clin. Med., 10.","DOI":"10.3390\/jcm10051061"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1159\/000513331","article-title":"Worse Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients with Autoimmune Hepatitis Features","volume":"39","author":"Wen","year":"2021","journal-title":"Dig. Dis."},{"key":"ref_24","first-page":"392","article-title":"Characteristics and Inpatient Outcomes of Primary Biliary Cholangitis and Autoimmune Hepatitis Overlap Syndrome","volume":"9","author":"Jiang","year":"2021","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S2468-1253(18)30163-8","article-title":"Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: Development and validation of the UDCA Response Score","volume":"3","author":"Carbone","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.cgh.2018.12.028","article-title":"Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis","volume":"17","author":"Cheung","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/ajg.2016.479","article-title":"Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers","volume":"112","author":"Floreani","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Gazda, J., Drazilova, S., Janicko, M., Grgurevic, I., Kanizaj, T.F., Koller, T., Bodorovska, B., Bozin, T., Mijic, M., and Rob, Z. (2021). Prognostic Factors in Primary Biliary Cholangitis: A Retrospective Study of Joint Slovak and Croatian Cohort of 249 Patients. J. Pers. Med., 11.","DOI":"10.3390\/jpm11060495"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.cgh.2020.08.006","article-title":"Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis","volume":"19","author":"Gerussi","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/19\/4551\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:07:57Z","timestamp":1760166477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/19\/4551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":30,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["jcm10194551"],"URL":"https:\/\/doi.org\/10.3390\/jcm10194551","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,30]]}}}